Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Immuron Ltd ADR (IMRN)

Immuron Ltd ADR (IMRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,374
  • Shares Outstanding, K 5,729
  • Annual Sales, $ 3,220 K
  • Annual Income, $ -4,550 K
  • EBIT $ 0 M
  • EBITDA $ -6 M
  • 60-Month Beta 1.35
  • Price/Sales 3.49
  • Price/Cash Flow N/A
  • Price/Book 1.34

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.7700 +9.60%
on 12/03/24
2.4100 -19.50%
on 12/10/24
+0.0601 (+3.20%)
since 11/22/24
3-Month
1.7334 +11.92%
on 11/13/24
2.8670 -32.33%
on 10/01/24
-0.8300 (-29.96%)
since 09/24/24
52-Week
1.5900 +22.01%
on 02/01/24
5.9600 -67.45%
on 03/07/24
-0.0100 (-0.51%)
since 12/22/23

Most Recent Stories

More News
Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing

NEW YORK, NY / ACCESSWIRE / December 3, 2024 / Investor Summit Group, committed to advancing the MicroCap and SmallCap investment community, announces that the November 21, 2024 Winter Investor Summit...

IMRN : 1.9400 (-2.29%)
ULY : 0.5000 (unch)
IMUX : 1.0500 (-1.87%)
NMTC : 0.7698 (+3.75%)
SNGX : 2.86 (+0.70%)
TMG.VN : 0.195 (unch)
BLGO : 0.1928 (+1.53%)
FET : 14.99 (+1.56%)
ACFN : 18.0000 (+2.86%)
NRBO : 2.36 (+0.43%)
TGCB : 0.0850 (+6.25%)
SOTK : 4.16 (-1.72%)
Immuron Limited CEO to Present at Small Cap Growth Virtual Investor Conference on December 5, 2024

Immuron Limited CEO Steven Lydeamore will present at the Small Cap Growth Virtual Investor Conference on December 5, 2024.Quiver AI SummaryImmuron Limited announced that CEO Steven Lydeamore will present...

IMRN : 1.9400 (-2.29%)
Immuron Limited Announces Participation in the LD Micro Main Event XVI

Presentation on Wednesday, October 4th at 11:00 PTMelbourne, Australia--(Newsfile Corp. - September 18, 2023) - Immuron Limited (NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical...

IMRN : 1.9400 (-2.29%)
Immuron Limited Announces Participation in the LD Micro Invitational XIII

Melbourne, Australia--(Newsfile Corp. - May 16, 2023) - Immuron Limited (ASX: IMC) (NASDAQ: IMRN) announced today that it will be presenting at the 13th Annual LD Micro Invitational at the Luxe Sunset...

IMRN : 1.9400 (-2.29%)
Global Alzheimer’s Disease Diagnostics & Therapeutics Market Expected to Reach $9.6 Billion by 2027

Palm Beach, FL – May 9, 2023 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease (AD) is a progressive and neurodegenerative disorder that attacks the brain’s nerve cells or neurons,...

IMC.AX : 0.080 (+2.56%)
SILO : 0.9586 (+8.51%)
LLY : 795.67 (-0.08%)
ACOR : 0.6610 (-24.86%)
TRVN : 1.8000 (+14.65%)
IMRN : 1.9400 (-2.29%)
Global Alzheimer's Disease Diagnostics & Therapeutics Market Expected to Reach $9.6 Billion by 2027

/PRNewswire/ -- Alzheimer's disease (AD) is a progressive and neurodegenerative disorder that attacks the brain's nerve cells or neurons, which results in loss...

SILO : 0.9586 (+8.51%)
LLY : 795.67 (-0.08%)
ACOR : 0.6610 (-24.86%)
TRVN : 1.8000 (+14.65%)
IMRN : 1.9400 (-2.29%)
Immuron US DoD Naval Medical Research Center Receives feedback on IND Application for New Campylobacter ETEC Therapeutic

MELBOURNE, Australia, July 26, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on...

IMRN : 1.9400 (-2.29%)
IMC.AX : 0.080 (+2.56%)
Immuron North American Travelan® Sales up 494% and Global sales up 431%

Highlights: North American FY22 Travelan® sales increased by +494% to $0.6MGlobal sales increased by 431% to $0.9MAustralian FY22 sales increased by...

IMRN : 1.9400 (-2.29%)
IMC.AX : 0.080 (+2.56%)
Immuron Receives European Patent Notification on Drug Composition to Treat Clostridioides difficile Associated Disease

MELBOURNE, Australia, July 07, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on...

IMRN : 1.9400 (-2.29%)
IMC.AX : 0.080 (+2.56%)
Immuron US DoD Naval Medical Research Center Submits IND Application for New Campylobacter ETEC Therapeutic

Key Points US Naval Medical Research Centre (NMRC) submits IND application to the U.S. Food and Drug administration (FDA)Two human phase II clinical...

IMRN : 1.9400 (-2.29%)
IMC.AX : 0.080 (+2.56%)

Business Summary

Immuron Limited is a bio pharmaceutical Microbiome company. It focused on oral immunotherapy using polyclonal antibody products for humans. The company is involved in developing therapeutic products in NASH, ASH and other diseases mediated through gut disbiosis. Immuron Limited is based in Armadale,...

See More

Key Turning Points

3rd Resistance Point 1.9400
2nd Resistance Point 1.9400
1st Resistance Point 1.9400
Last Price 1.9400
1st Support Level 1.9400
2nd Support Level 1.9400
3rd Support Level 1.9400

See More

52-Week High 5.9600
Fibonacci 61.8% 4.2907
Fibonacci 50% 3.7750
Fibonacci 38.2% 3.2593
Last Price 1.9400
52-Week Low 1.5900

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar